ResistAid May Boost Immunity

ALLENDALE, N.J.A new study sponsored by Lonza demonstrated a positive immune response by the Larch Arabinogalactan (LAG)-based ResistAid. Presented at the 50th Annual Meeting of the American College of Nutrition in Orlando, Fla., the results of the randomized, double blind, placebo-controlled, parallel-group study showed ResistAid increased the antibody (Ab) response to the 23-valent pneumococcal (pneumonia) vaccine.

The study tested the hypothesis that ingestion of ResistAid would selectively enhance the antibody response to the pneumoccocal (pneumonia) vaccine in healthy adults. The use of this research model is not intended to suggest the use of ResistAid in conjunction with any vaccine, or that the product helps prevent, cure or mitigate pneumonia or any other disease; rather, it provides additions to the body of research that suggests dietary intake of ResistAid may help support healthy immune function. The 72-day trial showed ResistAid positively modulated immune function by increasing the antibody response in healthy volunteers without increasing the non-specific innate immune response. Specifically, the group that ingested ResistAid demonstrated a higher IgG Ab response to the vaccine than the placebo group in two Ab subtypes (18C and 23F) at both day 51 (P=0.006 and P=0.002, respectively) and at day 72 (P=0.008 and P=0.003). There was no effect from the vaccine or LAG on salivary IgA, white blood cell count, inflammatory cytokines or complement.